ArticleArchives of toxicology2025
Characterizing the in vitro metabolic features of seven α-pyrrolidinophenone-derived synthetic cathinone-type new psychoactive substances.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Characterisation of the designer cathinone N-isopropylbutylone by a multi-technique approach and its metabolic profiling and stability assessment using dried matrix spots.Analytical and bioanalytical chemistry · 2026Article
- Phase I Metabolism of Novel Phencyclidine Derivative 3-Cl-PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post-Mortem Case.Drug testing and analysis · 2026Article
- Comprehensive metabolic profiling of the new designer stimulant MDPiHP-in vitro and in vivo identification of potential biomarkers for detection in human samples.Analytical and bioanalytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Synthetic cathinone-type new psychoactive substances (SCa-NPS) are the most representative subclass of synthetic stimulants, a major category of third-generation drugs monitored by the United Nations Office on Drugs and Crime. SCa-NPS rank second only to synthetic cannabinoid receptor agonists in prevalence and are characterized by rapid derivation and metabolism. This study investigated the in vitro metabolism of 3',4'-tetramethylene-α-pyrrolidinovalerophenone (TH-PVP), for which no metabolic data currently exists, using a human liver microsomal model. Ultra-high-performance liquid chromatography-tandem quadrupole-orbitrap mass spectrometry was used to analyze TH-PVP metabolites. By comparing mass spectrometry (MS) data with literature reports and analyzing cleavage patterns, 27 metabolites across 12 categories were identified. The primary metabolic pathways-hydroxylation, β-ketoreduction, and their combinations-accounted for 91.57% of total metabolites. Building on this foundation, the metabolism of six other α-pyrrolidinopentanone-structured SCa-NPS was examined. Structural effects on α-pyrrolidinophenone-derived SCa-NPS (PP SCa-NPS) metabolism were analyzed. The β-ketoreduction metabolite content showed a linear relationship with both the Hammett substituent constants on the phenyl ring and the energy difference between the lowest unoccupied and highest occupied molecular orbitals of the parent drug. Regarding hydroxylation metabolism, TH-PVP analysis revealed preferred hydroxylation on sp
Indexed as
Identifiers
40536547What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.